<DOC>
	<DOCNO>NCT02351024</DOCNO>
	<brief_summary>The Sponsor develop new form naproxen ( study drug , OXP005 ) , potential treatment rheumatic painful condition . The study compare study drug already market formulation prescription strength naproxen ( NaprosynÂ® reference product ) look single dose drug take body . The safety tolerability drug also assess .</brief_summary>
	<brief_title>Phase I Study PK Study With OXP005 Naprosyn</brief_title>
	<detailed_description />
	<mesh_term>Naproxen</mesh_term>
	<criteria>Healthy male subject nonpregnant , non breast feed healthy female subject age 18 55 year Body mass index 18.0 30.0 kg/m2 History current significant disease condition include disease condition affect haematopoietic , cardiovascular , renal , hepatic , endocrine , pulmonary , central nervous , immunological , dermatological , gastrointestinal body system</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>